Physician profile

Mariya Syed

Hudson, FL

NPI 1194417113

$739.17

in general payments reported to CMS, 2019-2025

7 companies · $593 in 2025

The $593 reported for 2025 was more than what 81% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$739.17

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $292.41 2025 Tremfya, Simponi Aria, Darzalex
Genzyme Corporation $287.92 2024-2025
Glaxosmithkline, LLC. $74.75 2025
Ucb, INC. $27.05 2025 Bimzelx
Radius Health, INC. $19.55 2025 Tymlos
Sobi, INC $18.88 2025
Csl Behring $18.61 2025 Hizentra

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mariya Syed

$739.17

in general payments reported 2019-2025

Years
2024-2025
Top company
Janssen Biotech, INC.
Context
The $593 reported for 2025 was more than what 81% of providers received nationally.

https://glasscript.com/doctor/11684528/mariya-syed

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.